Dichloromethanediphosphonic acid en es it fr

Dichloromethanediphosphonic acid Brand names, Dichloromethanediphosphonic acid Analogs

Dichloromethanediphosphonic acid Brand Names Mixture

  • No information avaliable

Dichloromethanediphosphonic acid Chemical_Formula

CH4Cl2O6P2

Dichloromethanediphosphonic acid RX_link

No information avaliable

Dichloromethanediphosphonic acid fda sheet

Dichloromethanediphosphonic acid msds (material safety sheet)

Dichloromethanediphosphonic_acid MSDS

Dichloromethanediphosphonic acid Synthesis Reference

No information avaliable

Dichloromethanediphosphonic acid Molecular Weight

244.892 g/mol

Dichloromethanediphosphonic acid Melting Point

250 oC

Dichloromethanediphosphonic acid H2O Solubility

395 mg/L

Dichloromethanediphosphonic acid State

Solid

Dichloromethanediphosphonic acid LogP

-0.906

Dichloromethanediphosphonic acid Dosage Forms

Capsules; Solution

Dichloromethanediphosphonic acid Indication

For the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.

Dichloromethanediphosphonic acid Pharmacology

Clodronate is a first generation (non-nitrogenous) bisphosphonate in the same family as etidronate and tiludronate. Clodronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the clodronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Clodronate has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.

Dichloromethanediphosphonic acid Absorption

After oral administration, absorption is estimated at 1–3% of the ingested dose because of the low uptake from the gastrointestinal tract.

Dichloromethanediphosphonic acid side effects and Toxicity

Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients.

Dichloromethanediphosphonic acid Patient Information

No information avaliable

Dichloromethanediphosphonic acid Organisms Affected

Humans and other mammals